Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
07 mars 2023 16h02 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
05 mars 2023 18h30 HE
|
Immuneering Corporation
Broad response demonstrated through deep cyclic inhibition of MAPK pathway, independent of specific RAS mutation Phase 1/2a clinical trial with IMM-1-104 underway in patients with advanced solid...
Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock
02 mars 2023 21h15 HE
|
Revolution Medicines, Inc.
REWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Announces Commencement of Public Offering of Common Stock
01 mars 2023 16h17 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress
27 févr. 2023 16h05 HE
|
Revolution Medicines, Inc.
Early clinical data on RMC-6236 provided in support of RAS(ON) Inhibitor platform validation Additional data releases for RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C) expected in 2023 RMC-9805...
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023
21 févr. 2023 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
HOOKIPA Achieves $10 Million Milestone Payment in Development of Immunotherapy for KRAS-Mutated Cancers
13 févr. 2023 07h00 HE
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Feb. 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus...
Outlook on the KRAS Inhibitors Global Market, Drug Price, Sales, & Clinical Trials Insight to 2029
08 févr. 2023 07h38 HE
|
Research and Markets
Dublin, Feb. 08, 2023 (GLOBE NEWSWIRE) -- The "Global KRAS Inhibitors Market, Drug Price, Sales, & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's...
Revolution Medicines to Participate in Upcoming Investor Conferences
02 févr. 2023 07h00 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines to Present at 41st Annual J.P. Morgan Healthcare Conference
03 janv. 2023 07h00 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...